Featuring Adam Friedman, MD Dr. Adam Friedman gave a lively introduction to oncodermatology this morning. As cancer mortality has gone down, survivors of cancer with perpetual skin issues has gone up. A 2008 statistic reveals that among adverse events from phase 1 and 2 trials, 8% of these are dermatologic complaints. Of interest, many of …
So-called ‘hedgehog pathway inhibitors’ (HPI) such as vismodegib and sonidegib are effective therapies for treating basal cell carcinoma (BCC). HPI target overactive signals in the hedgehog molecular pathway that lead to the proliferation of cancer cells. However, when inhibiting the cancer cells, HPI also inhibit hair follicle (HF) growth which leads to hair loss in …